Abacavir has no prothrombotic effect on platelets in vitro.

Area of Science:

• Cardiovascular Medicine
• Hematology
• Infectious Diseases

Background:

• Abacavir use in HIV patients is linked to increased myocardial infarction risk, but findings are inconsistent.
• The direct impact of abacavir on platelet function remains unclear.

Purpose of the Study:

• To investigate the direct effect of abacavir on platelet activation and aggregation.
• To utilize platelets from both healthy donors and HIV-infected patients on antiretroviral therapy.

Main Methods:

• Platelet-rich plasma and whole blood from healthy donors and HIV patients were treated with abacavir or its metabolite.
• Platelet aggregation was assessed using turbidimetry and high shear stress.
• Thrombin generation was measured to evaluate procoagulant potential.

Main Results:

• Abacavir and carbovir diphosphate significantly enhanced collagen-induced platelet aggregation in healthy donors at a specific concentration.
• No significant effects were observed on platelet aggregation induced by other agonists, high shear stress, or thrombin generation.
• Similar results were obtained when abacavir was pre-applied to blood from HIV-infected patients.

Conclusions:

• Abacavir does not appear to significantly influence platelet activation in vitro.
• A potential synergistic effect with other medications could contribute to platelet activation and myocardial infarction pathogenesis.